PEOPLE - Changes at FlowMedica:
This article was originally published in Clinica
FlowMedica (Fremont, California) has named Gordon Snyder vice-president of sales, as the company moves to commercialise its products. The firm develops intervascular systems to deliver therapeutic agents direct to the kidneys via the renal arteries (targeted renal therapy - TRT) to prevent and treat kidney dysfunction resulting from radiographic contrast media, administered during coronary intervention and diagnostic procedures. Prior to joining FlowMedica, Mr Snyder had managed sales at Novoste and Medtronic among other device companies.
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”